mRNA COVID-19 Vaccines Immunogenic in Immunosuppressed Patients
Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy
Inflammatory Bowel Disease
Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine
COVID-19 Vaccination of IBD Patients: Do Biologics Impact Serological Responses?
Patients with IBD were compared to control groups without IBD, which included 14 completely vaccinated healthcare workers and 29 vaccinated healthy volunteers.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
23andMe Develops Drug Compound Using Consumer Genetic Data
23andMe, a consumer genetics company, has licensed its first drug compound to Almirall, a global pharmaceutical company.
ED Visits, Hospitalization Trends Examined in Patients With IBD
Trends in the utilization of emergency department (ED) care and hospitalization among patients with inflammatory bowel disease (IBD) were investigated in a new study.
Safety of IV Iron Products Compared in Patients With IBD
The safety profiles of various IV iron products were compared in a study involving patients with inflammatory bowel disease IBD being treated for iron deficiency anemia.
Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
IBD Treatments Compared in Older Crohn Disease, Ulcerative Colitis Patients
In older patients with inflammatory bowel disease (IBD), tumor necrosis factor alpha antagonist (anti-TNF) therapy and vedolizumab (an integrin receptor antagonist) were found to be comparable with regard to both safety and effectiveness, according to a study published in Alimentary Pharmacology & Therapeutics.
Limited Data on Combination Biologic Therapy for IBD, Says Study
The authors point out how, unlike other autoinflammatory conditions, “IBD has the benefit of effective and safe gut specific anti-integrin therapies which can provide a platform off of which combinations can be employed.”
